Aakash Healthcare, Medtronic open North India’s first dedicated vein clinic

IMT News Desk
IMT News Desk
· 2 min read

The specialised clinic will provide advanced, minimally invasive treatments for vein-related conditions

Aakash Healthcare Super Specialty Hospital, in collaboration with Medtronic, has launched the Aakash Vein Clinic, North India’s first dedicated centre for comprehensive vein care. The specialised clinic will provide advanced, minimally invasive treatments for vein-related conditions, enabling faster recovery and better long-term outcomes for patients.

The inauguration at Aakash Healthcare, Dwarka brought together leading doctors, healthcare professionals, and industry experts. The event featured insightful discussions on the increasing need for specialised vein treatments and how Medtronic’s cutting-edge technology is revolutionising vascular care in India.

Dr Aashish Chaudhry, MD, Aakash Healthcare, mentioned, “Our goal with the Aakash Vein Clinic is to provide a dedicated centre where patients receive comprehensive vein care, from diagnosis to advanced treatment, all under one roof. This initiative reflects our ongoing commitment to delivering world-class healthcare solutions.”

Dr Abhishek Bansal, Senior Consultant and Chief of Interventional Radiology, discussed the latest advancements in vein treatments and the growing demand for expert care.

“The collaboration of Medtronic with Aakash Hospital is a testament to our commitment to advancing healthcare and improving patient outcomes. By providing cutting-edge solutions and innovative treatments, we aim to empower physicians to enhance the quality of care and provide the right guidance for patients with varicose veins. Our mission remains steadfast: to alleviate pain, restore health, and extend life through continuous innovation and dedication to excellence,” said Prateek Tiwari, Senior Director, Neuroscience & Specialty Therapies, Medtronic India.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk